Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.39 |
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | ZAP70 | P43403 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8426757 | 0.83 | CHRNB2 (0.37) | SYKZAP70ADORA3TTK | |
| SCHEMBL8426788 | 0.76 | AURKA (0.35) | ADORA3TTK | |
| SCHEMBL8429587 | 0.76 | ADORA3 (0.38) | ADORA3 | |
| SCHEMBL12473231 | 0.76 | AURKA (0.34) | SYKADORA3 | |
| SCHEMBL8239866 | 0.75 | AURKA (0.56) | BRD4TTK | |
| SCHEMBL8427744 | 0.75 | MAPKAPK5 (0.38) | SYKADORA3KMT2A | |
| SCHEMBL8429895 | 0.74 | PAK4 (0.42) | ADORA3TTKKARS1 | |
| SCHEMBL8427842 | 0.74 | AURKA (0.32) | ADORA3 | |
| SCHEMBL8427933 | 0.73 | ZAP70 (0.35) | SYKZAP70ADORA3TTKKARS1 | |
| SCHEMBL8426616 | 0.73 | PAK4 (0.37) | SYKADORA3KARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576085-B2 | Imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | SCHERING CORPORATION | 2006-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106023-A1 | Novel imidazopyrazines as cyclin dependent kinase inhibitors | CDK2, CDKN1A, CDK1 | BRD4 200/4885SYK 1991/4885ZAP70 852/4885 |
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | BRD4 755/4885SYK 627/4885ZAP70 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.